Baillie Gifford & CO Ab Cellera Biologics Inc. Put Options Transaction History
Baillie Gifford & CO
- $128 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ABCL
# of Institutions
149Shares Held
115MCall Options Held
488KPut Options Held
476K-
Baker Bros. Advisors LP New York, NY27.5MShares$126 Million0.96% of portfolio
-
Capital World Investors Los Angeles, CA13.4MShares$61.1 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL8.47MShares$38.7 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$20.8 Million0.02% of portfolio
-
Two Sigma Investments, LP New York, NY4.11MShares$18.8 Million0.03% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $1.3B
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...